Citigroup Cuts Boston Scientific (NYSE:BSX) Price Target to $87.00

10 Apr 2026, 03:20 by Amy Steele · The Cerbat Gem

Boston Scientific (NYSE:BSX – Free Report) had its price objective trimmed by Citigroup from $94.00 to $87.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

A number of other equities analysts also recently commented on the stock. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a research note on Monday, March 16th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Robert W. Baird lowered their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Barclays lowered their target price on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $104.05.

Check Out Our Latest Stock Analysis on BSX

Boston Scientific Stock Down 2.0%

Boston Scientific stock opened at $61.31 on Tuesday. Boston Scientific has a twelve month low of $60.59 and a twelve month high of $109.50. The stock’s fifty day simple moving average is $72.11 and its 200-day simple moving average is $88.38. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $91.12 billion, a P/E ratio of 31.60, a P/E/G ratio of 0.97 and a beta of 0.78.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the company earned $0.70 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Hedge funds have recently made changes to their positions in the business. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Steph & Co. acquired a new stake in shares of Boston Scientific during the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific during the third quarter worth about $25,000. Finally, Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Recent company fundamentals remain a support: Boston Scientific reported a recent quarter with revenue growth and an EPS beat, and management set FY‑2026 guidance — facts that underpin longer‑term earnings expectations.
Neutral Sentiment: Startups and competitors continue to raise capital in the thrombectomy and endovascular spaces, keeping competition and M&A dynamics active (could pressure or spur strategic moves). E2 raises $80M to market thrombectomy platform
Neutral Sentiment: Industry commentary and longer‑term analyst pieces debate valuation after a sharp pullback; these pieces can encourage opportunistic buyers but also reflect lingering investor caution. Is It Time To Revisit Boston Scientific (BSX)…
Negative Sentiment: Multiple law firms have filed or are soliciting clients in a securities class‑action covering the July 23, 2025–Feb 3, 2026 period and are reminding investors of a May 4, 2026 lead‑plaintiff deadline — a sustained wave of litigation notices increases legal uncertainty and potential liability. Representative filing/notice: ROSEN law firm notice re BSX class action
Negative Sentiment: Regulatory/transaction scrutiny: an investor alert has been issued about the proposed Penumbra acquisition (questions over price/process could complicate the deal and create headline risk). Penumbra investor alert re Boston Scientific deal
Negative Sentiment: Sell‑side and research downgrades/estimate trims: Citigroup and other firms have lowered expectations or price targets, and at least one regional analyst trimmed FY‑2026 EPS modestly — pressure on near‑term sentiment and target prices. Citigroup lowers expectations for BSX

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.